Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.25 and traded as low as $0.1950. Northwest Biotherapeutics shares last traded at $0.2065, with a volume of 2,140,465 shares.

Northwest Biotherapeutics Price Performance

The company’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.25. The company has a market cap of $332.82 million, a P/E ratio of -0.01 and a beta of -0.81.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.